Five Prime Therapeutics (FPRX) has an average broker rating of 1.5, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Five Prime Therapeutics (FPRX) : The consensus price target for Five Prime Therapeutics (FPRX) is $45.33 for the short term with a standard deviation of $4.51. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $50, however, the pessimist price target for the company is $41.
For the current week, the company shares have a recommendation consensus of Buy.
Five Prime Therapeutics (NASDAQ:FPRX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.37 and $49.98 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $51.73. The buying momentum continued till the end and the stock did not give up its gains. It closed at $51.68, notching a gain of 2.38% for the day. The total traded volume was 805,370 . The stock had closed at $50.48 on the previous day.
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Companys product candidates include FPA008, FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R), that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b), which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. Its partner, GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma.